A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune Inc.
Replimune Inc.
ModernaTX, Inc.
BioInvent International AB
7 Hills Pharma, LLC
Incyte Corporation
Biogen
Rampart Health, L.L.C.
Clinigen, Inc.
SQZ Biotechnologies
Idera Pharmaceuticals, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb